

CLAIMS

1. Transdermal therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising a backing layer, ^{and containing oestradiol and more norethisterone} reservoir supersaturated with active ingredients, ^{which is} attached to said backing layer and ^{is} prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, ^{wherein} ~~characterized in that~~ the crystallization inhibitor is an amino-containing polymer.

2. Transdermal therapeutic system according to Claim 1, ^{wherein} ~~characterized in that~~ the crystallization inhibitor is selected from polymers based on butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate, ^{said polymers having} in particular ~~in~~ a molar ratio of 1:2:1, polyaminoamides, polyaminoimidazolines, polyetherurethaneamines, polyamines and polyglucosamines.

3. Transdermal therapeutic system according to either of Claims 1 and 2, ~~characterized in that~~ the reservoir comprises one or more crystallization inhibitors in a proportion of from 0.05-30% by weight.

4. Transdermal therapeutic system according to one or more of Claims 1 - 3, ~~characterized in that~~ the reservoir comprises oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15, preferably from 1:3 to 1:7, and in an overall concentration of up to 25% by weight.

5. Transdermal therapeutic system according to ^{Claim 1} ~~one or more of Claims 1 - 4~~, ^{wherein} ~~characterized in that~~ the reservoir includes a constituent from the group of ageing inhibitors, plasticizers, antioxidants and absorption improvers, the plasticizer being used in a concentration of 0-5% by weight

and the ageing inhibitor in a concentration of 0.1-2% by weight.

B3
Cont

6. Transdermal therapeutic system according to ^{claim 1} ~~one or~~
~~more of Claims 1 - 5,~~ ^{wherein} characterized in that the pressure-
sensitive adhesive is ^{at} a solvent-based adhesive, a
dispersion adhesive, a hot-melt adhesive ^{and} ~~or~~ a UV-
crosslinkable adhesive.

a
a
Sub
a
a

7. Transdermal therapeutic system according to ^{claim 1} ~~one or~~
~~more of Claims 1 - 6,~~ ^{wherein} characterized in that the reservoir
^{at least} consists of ~~two or more~~ layers.

a
a
a

8. Transdermal therapeutic system according to one or
more of Claims 1 - 7, characterized in that the reservoir
has a layer thickness of 0.02 mm-0.500 mm, preferably
0.030-0.200 mm.

Sub
a
8

9. Transdermal therapeutic system according to ^{claim 1} ~~one or~~
~~more of Claims 1 - 8,~~ ^{wherein} characterized in that the reservoir
is provided with an additional pressure-sensitive adhesive
layer ~~and/or with a pressure-sensitive adhesive margin.~~

a
a
a

10. Use of the transdermal therapeutic system
corresponding to one or more of Claims 1-9 for therapeutic
applications in human medicine.

add
a 9